$10.48
+0.99
(+10.43%)▲
Live
6.11%
Downside
Day's Volatility :10.63%
Upside
4.81%
38.93%
Downside
52 Weeks Volatility :80.69%
Upside
68.37%
Period | Cvrx Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -3.36% | 3.6% | 0.0% |
6 Months | -35.4% | 10.2% | 0.0% |
1 Year | -25.57% | 19.6% | 0.0% |
3 Years | -39.36% | 16.8% | -23.0% |
Market Capitalization | 176.5M |
Book Value | $2.55 |
Earnings Per Share (EPS) | -2.57 |
Wall Street Target Price | 13.8 |
Profit Margin | -122.52% |
Operating Margin TTM | -118.35% |
Return On Assets TTM | -32.82% |
Return On Equity TTM | -74.91% |
Revenue TTM | 44.4M |
Revenue Per Share TTM | 2.1 |
Quarterly Revenue Growth YOY | 24.3% |
Gross Profit TTM | 17.5M |
EBITDA | -54.9M |
Diluted Eps TTM | -2.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.61 |
EPS Estimate Next Year | -2.07 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.47 |
What analysts predicted
Upside of 31.68%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 6.3M | - |
Net Income | -14.6M | - |
Net Profit Margin | -233.87% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.1M | ↓ 3.26% |
Net Income | -14.1M | ↓ 3.58% |
Net Profit Margin | -233.09% | ↑ 0.78% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 13.0M | ↑ 115.36% |
Net Income | -43.1M | ↑ 205.32% |
Net Profit Margin | -330.45% | ↓ 97.36% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 22.5M | ↑ 72.36% |
Net Income | -41.4M | ↓ 3.83% |
Net Profit Margin | -184.38% | ↑ 146.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 39.3M | ↑ 74.89% |
Net Income | -41.2M | ↓ 0.55% |
Net Profit Margin | -104.85% | ↑ 79.53% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.0M | ↑ 11.19% |
Net Income | -11.4M | ↑ 7.95% |
Net Profit Margin | -142.55% | ↑ 4.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.5M | ↑ 19.06% |
Net Income | -11.7M | ↑ 2.44% |
Net Profit Margin | -122.64% | ↑ 19.91% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.5M | ↑ 10.64% |
Net Income | -9.0M | ↓ 22.66% |
Net Profit Margin | -85.73% | ↑ 36.91% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.3M | ↑ 7.55% |
Net Income | -9.2M | ↑ 1.69% |
Net Profit Margin | -81.05% | ↑ 4.68% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.8M | ↓ 4.73% |
Net Income | -22.2M | ↑ 142.13% |
Net Profit Margin | -206.0% | ↓ 124.95% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.8M | ↑ 9.63% |
Net Income | -14.0M | ↓ 36.77% |
Net Profit Margin | -118.82% | ↑ 87.18% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 29.1M | - |
Total Liabilities | 308.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 64.8M | ↑ 122.55% |
Total Liabilities | 358.0M | ↑ 16.18% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 152.5M | ↑ 135.5% |
Total Liabilities | 6.6M | ↓ 98.16% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 124.9M | ↓ 18.1% |
Total Liabilities | 15.8M | ↑ 139.14% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 115.2M | ↓ 7.77% |
Total Liabilities | 39.3M | ↑ 149.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 122.7M | ↓ 1.8% |
Total Liabilities | 23.0M | ↑ 46.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 115.0M | ↓ 6.29% |
Total Liabilities | 25.0M | ↑ 8.5% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 106.4M | ↓ 7.45% |
Total Liabilities | 23.6M | ↓ 5.73% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 115.2M | ↑ 8.29% |
Total Liabilities | 39.3M | ↑ 66.61% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 106.2M | ↓ 7.86% |
Total Liabilities | 39.9M | ↑ 1.6% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 96.0M | ↓ 9.6% |
Total Liabilities | 40.7M | ↑ 2.06% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.8M | - |
Investing Cash Flow | -106.0K | - |
Financing Cash Flow | 29.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.1M | ↑ 25.9% |
Investing Cash Flow | -311.0K | ↑ 193.4% |
Financing Cash Flow | 49.8M | ↑ 68.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.7M | ↑ 72.29% |
Investing Cash Flow | -1.2M | ↑ 280.39% |
Financing Cash Flow | 111.9M | ↑ 124.74% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -42.7M | ↑ 53.89% |
Investing Cash Flow | -685.0K | ↓ 42.1% |
Financing Cash Flow | 7.5M | ↓ 93.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.2M | ↓ 5.46% |
Investing Cash Flow | -240.0K | ↑ 203.8% |
Financing Cash Flow | 7.6M | ↑ 6.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.8M | ↑ 24.97% |
Investing Cash Flow | -143.0K | ↓ 40.42% |
Financing Cash Flow | 473.0K | ↓ 93.75% |
Sell
Neutral
Buy
Cvrx Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Cvrx Inc | 5.33% | -35.4% | -25.57% | -39.36% | -48.81% |
Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Cvrx Inc | 0.14 | NA | NA | -2.61 | -0.75 | -0.33 | NA | 2.55 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Cvrx Inc | Buy | $176.5M | -48.81% | 0.14 | -122.52% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Cvrx Inc
Revenue is up for the last 2 quarters, 10.77M → 11.80M (in $), with an average increase of 8.8% per quarter
Netprofit is up for the last 2 quarters, -22.18M → -14.02M (in $), with an average increase of 58.1% per quarter
In the last 1 year, Boston Scientific Corp. has given 76.0% return, outperforming this stock by 102.5%
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 135.7%
Johnson & Johnson
NEA Management Company, LLC
BlackRock Inc
Vanguard Group Inc
Soleus Capital Management, L.P.
Emerald Advisers, LLC
cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.
Organization | Cvrx Inc |
Employees | 200 |
CEO | Mr. Kevin Hykes |
Industry | Healthcare |
Lantern Pharma Inc
$10.48
+10.43%
Surmodics Inc
$10.48
+10.43%
Precigen Inc
$10.48
+10.43%
Redhill Biopharma Ltd-sp Adr
$10.48
+10.43%
Mind Medicine (mindmed) Inc
$10.48
+10.43%
Sonida Senior Living Inc.
$10.48
+10.43%
22nd Century Group Inc
$10.48
+10.43%
Enhabit Inc
$10.48
+10.43%
Kiniksa Pharmaceuticals International Plc
$10.48
+10.43%